| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (NCT07621601) | Hansoh BioMedical R&D Company | 2026-07-31 |
| PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC (NCT07645222) | Hansoh BioMedical R&D Company | 2026-06-15 |
| A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (NCT07464327) | Hansoh BioMedical R&D Company | 2026-03-31 |
| HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (NCT07462923) | Hansoh BioMedical R&D Company | 2026-01-29 |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. (NCT07283367) | Hansoh BioMedical R&D Company | 2025-12-22 |
| Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (NCT07186452) | Hansoh BioMedical R&D Company | 2025-09-23 |
| Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (NCT07115446) | Hansoh BioMedical R&D Company | 2025-08-19 |
| A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis (NCT06844799) | Hansoh BioMedical R&D Company | 2025-06-10 |
| A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors (NCT06936735) | Hansoh BioMedical R&D Company | 2025-05-29 |
| A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (NCT07181343) | Hansoh BioMedical R&D Company | 2025-05-28 |
| Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure (NCT06935409) | Hansoh BioMedical R&D Company | 2025-04-25 |
| A Study of HS-20122 in Patients With Advanced Solid Tumors (NCT06927570) | Hansoh BioMedical R&D Company | 2025-04-15 |
| A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis (NCT06926582) | Hansoh BioMedical R&D Company | 2025-04-09 |
| HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (NCT06855069) | Hansoh BioMedical R&D Company | 2025-03-13 |
| A Study of HS-20110 in Participants With Advanced Solid Tumors (NCT06892379) | Hansoh BioMedical R&D Company | 2025-02-26 |
| ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (NCT06699576) | Hansoh BioMedical R&D Company | 2024-12-20 |
| Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors (NCT06621563) | Hansoh BioMedical R&D Company | 2024-12-14 |
| ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer (NCT06052423) | Hansoh BioMedical R&D Company | 2024-11-30 |
| A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (NCT06672393) | Hansoh BioMedical R&D Company | 2024-11-04 |
| A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (NCT06594965) | Hansoh BioMedical R&D Company | 2024-10-30 |
| A Study of HS-20124 in Patients with Advanced Solid Tumors (NCT06763159) | Hansoh BioMedical R&D Company | 2024-10-30 |
| ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer (NCT06825624) | Hansoh BioMedical R&D Company | 2024-10-03 |
| A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer (NCT06526624) | Hansoh BioMedical R&D Company | 2024-09-30 |
| ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (NCT06498479) | Hansoh BioMedical R&D Company | 2024-07-04 |
| A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women (NCT06393673) | Hansoh BioMedical R&D Company | 2024-05-30 |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT06417008) | Hansoh BioMedical R&D Company | 2024-05-28 |
| ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (NCT06332170) | Hansoh BioMedical R&D Company | 2024-04-26 |
| HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (NCT06336707) | Hansoh BioMedical R&D Company | 2024-04-11 |
| Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. (NCT06144723) | Hansoh BioMedical R&D Company | 2024-03-01 |
| Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (NCT06176508) | Hansoh BioMedical R&D Company | 2024-02-26 |
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders (NCT06212245) | Hansoh BioMedical R&D Company | 2024-02-25 |
| HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (NCT06112704) | Hansoh BioMedical R&D Company | 2024-02-06 |
| ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors (NCT06001255) | Hansoh BioMedical R&D Company | 2024-01-18 |
| HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer (NCT06014190) | Hansoh BioMedical R&D Company | 2023-12-18 |
| ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT06007729) | Hansoh BioMedical R&D Company | 2023-12-18 |
| Study of HS-10384 in Participants of Chinese Postmenopausal Women (NCT06122181) | Hansoh BioMedical R&D Company | 2023-11-12 |
| A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (NCT06077331) | Hansoh BioMedical R&D Company | 2023-09-28 |
| A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (NCT05940116) | Hansoh BioMedical R&D Company | 2023-07-20 |
| ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas (NCT05830123) | Hansoh BioMedical R&D Company | 2023-06-08 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects (NCT05942625) | Hansoh BioMedical R&D Company | 2023-05-23 |